Published in IBI on October 10, 2025, by Benjamin Wilkin
Wilkin, B., (2025) Comparing Organoids and Patient-derived Xenograft Models for the Development of Antibody-drug Conjugates - Crown Bioscience. https://blog.crownbio.com/comparing-organoids-and-patient-derived-xenograft-models-for-the-development-of-antibody-drug-conjugates
Developing an oncology therapy requires a series of key decisions, each with the power to move a program forward or set it back. Pipelines are increas…
Read more
Immunooncology (IO) drug development increasingly depends on understanding human specific immune mechanisms. However, these subtle, highly coordinated…
Read more
In the rapidly evolving landscape of oncology drug discovery, antibody-drug conjugates (ADCs) represent one of the most promising therapeutic modaliti…
Read more
